NEW YORK, NY and SAN DIEGO, CA – February 9, 2017 – Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (NASDAQ:RGLS) in the United States District Court for the Southern District of California on behalf of persons or entities who purchased or otherwise acquired Regulus stock between January 21, 2016 and June 27, 2016, inclusive (the “Class Period”).
Investors who have incurred losses in shares of Regulus Therapeutics Inc. are urged to contact the firm immediately at firstname.lastname@example.org or (800) 575-0735 or (212) 545-4774.
If you have purchased shares of Regulus Therapeutics Inc. within the class period, you may, no later than April 3, 2017, request that the Court appoint you lead plaintiff of the proposed class.
The filed Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) patients treated with RG-101 were at increased risk of contracting jaundice; (2) consequently, the Company had overstated RG-101’s approval prospects and/or commercial viability; and (3) as a result of the foregoing, Regulus’s public statements were materially false and misleading at all relevant times.
On June 27, 2016, the Company announced that it had received verbal notice from the U.S. Food and Drug Administration (“FDA”) that the FDA had placed RG-101 on clinical hold after a second serious adverse event of jaundice was reported in a patient treated with the drug.
On this news, the Company’s share price fell $2.47, or more than 49%, to close at $2.54 on June 28, 2016.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at email@example.com.